Simple arm cuff before angioplasty may boost heart attack recovery
NCT ID NCT07689591
First seen Jul 08, 2026 · Last updated Aug 19, 2026 · Updated 4 times
Summary
This trial tests whether a noninvasive procedure called RE-START, which uses a blood pressure cuff to temporarily stop blood flow in the arm, can improve blood flow in the heart's arteries before standard angioplasty in people having a severe heart attack (STEMI). The study involves 500 adults who are stable enough to undergo the procedure within 12 hours of symptoms. The main goal is to see if this simple technique increases the chance of natural blood flow restoration in the blocked artery before the balloon is inserted.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- noninvasive artificial venous stasis (RE-START procedure)
- What this could lead to
- If effective, this simple, noninvasive procedure could improve blood flow before standard heart attack treatment, potentially reducing heart damage.
- What could go wrong
- This is a relatively early-stage trial, and the procedure may not improve outcomes or could cause discomfort. Results may not apply to all heart attack patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2026
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will include adult patients admitted to Firat University Hospital with acute ST-segment elevation myocardial infarction who are eligible for and planned to undergo primary percutaneous coronary intervention. Eligible patients will be randomized before coronary angiography to either the RE-START procedure group or the sham-control group, without delaying standard STEMI management or primary PCI.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Having presented within the first 12 hours of symptom onset Being hemodynamically stable (Killip Class I-II) * STEMI diagnosis confirmed by coronary angiography * Primary PCI (percutaneous coronary intervention) scheduled * No pathology in the upper extremity that would prevent cuff application * Be capable of providing informed consent and provide consent Exclusion Criteria: * Presence of cardiogenic shock (systolic blood pressure \< 90 mmHg and Killip Class III-IV) * Cardiac arrest occurring before or after the procedure * Need for resuscitation following failed thrombolysis * History of prior coronary artery bypass surgery * Concurrent acute aortic dissection * Venous thromboembolism or pulmonary embolism * History of an acute infection within the past 7 days * Chronic kidney disease requiring erythropoietin therapy or currently undergoing hemodialysis * Presence of liver failure or a hematologic disorder * Presence of any chronic inflammatory or autoimmune disease * History of any known malignancy (cancer) * Current treatment with glibenclamide, corticosteroids, antioxidant vitamins, or cyclosporine at the time of enrollment * History of chronic (daily) alcohol consumption * Contraindications to aspirin and/or clopidogrel * Failure to confirm a STEMI diagnosis via coronary angiography * Inability to provide informed consent * Pregnancy * First 6 months postpartum Conditions in which the administration of thrombolytics is contraindicated
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Stemi - ST elevation myocardial infarction are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Firat University
RECRUITINGElâzığ, Elaziğ, 23000, Turkey (Türkiye)
-
Firat University
RECRUITINGElâzığ, Merkez, 23000, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive chest pain registry reveals gaps between guidelines and real-world care in china
- Suction device may improve outcomes in heart attack patients with large clots
- AI blood test could spot heart attacks faster
- Heart attack patients may benefit from Clot-Busting drug before delayed procedure
- Heart attack patients to receive injectable gel that may limit damage
- Can a chinese herbal tablet help hearts heal after a heart attack?